Volume : 09, Issue : 05, May – 2022
Title:
22.A REVIEW ON EMERGING THERAPY OF CANCER
Authors :
Prashant Sen, Prashant Vishwakarma, Prince Jain, Rashi Jain, Mrs. Sunayana Kesharwani*
Abstract :
Every year, cancer kills millions of people throughout the world, and despite significant advances in medicine, there are still many difficulties that need to be addressed in order to enhance cancer treatment. As a result, oncological research is focusing its efforts on developing novel and effective therapies that can mitigate the negative effects of current treatments. Various technologies are now being tested in clinical trials or have previously been implemented in clinical practise. Bioengineering of extracellular vesicles and cells derived from patients has permitted the development of ad hoc systems and univocal targeting tactics, while nanomedicine contributes to the production of biocompatible materials for diagnostic and therapeutic applications. We will examine the most innovative advances in basic and applied cancer research in depth in this review.
Key words:Cancer, Therapy, Diagnostic, Therapeutic applications
Cite This Article:
Please cite this article in press Sunayana Kesharwani et al, A Review On Emerging Therapy Of Cancer., Indo Am. J. P. Sci, 2022; 09(5).,
Number of Downloads : 10
References:
1. Harbeck, N.; Gnant, M. Breast cancer. Lancet 2017, 389, 1134–1150.
2. Wang, H.; Zhang, C.; Zhang, J.; Kong, L.; Zhu, H.; Yu, J. The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: A SEER based study. Oncotarget 2017, 8, 26368–26379.
3. Provenzano, E.; Ulaner, G.A.; Chin, S.F. Molecular Classification of Breast Cancer. PET Clin. 2018, 13, 325–338.
4. Wang, D.Y.; Jiang, Z.; Ben-David, Y.; Woodgett, J.R.; Zacksenhaus, E. Molecular stratification within triple-negative breast cancer subtypes. Sci. Rep. 2019, 9, 19107.
5. Peinado, H.; Zhang, H.; Matei, I.R.; Costa-Silva, B.; Hoshino, A.; Rodrigues, G.; Psaila, B.; Kaplan, R.N.; Bromberg, J.F.; Kang, Y.; et al. Pre-metastatic niches: Organ-specific homes for metastases. Nat. Rev. Cancer 2017, 17, 302–317.
6. Mareel, M.; Leroy, A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol. Rev. 2003, 83, 337–376.
7. Au, S.H.; Storey, B.D.; Moore, J.C.; Tang, Q.; Chen, Y.L.; Javaid, S.; Sarioglu, A.F.; Sullivan, R.; Madden, M.W.; O’Keefe, R.; et al. Clusters of circulating tumor cells traverse capillary-sized vessels. Proc. Natl. Acad. Sci. USA 2016, 113, 4947–4952.
8. Lambert, A.W.; Pattabiraman, D.R.; Weinberg, R.A. Emerging Biological Principles of Metastasis. Cell 2017, 168, 670–691.
9. Yu, M.; Ting, D.T.; Stott, S.L.; Wittner, B.S.; Ozsolak, F.; Paul, S.; Ciciliano, J.C.; Smas, M.E.; Winokur, D.; Gilman, A.J.; et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012, 487, 510–513.
10. Felding-Habermann, B.; O’Toole, T.E.; Smith, J.W.; Fransvea, E.; Ruggeri, Z.M.; Ginsberg, M.H.; Hughes, P.E.; Pampori, N.; Shattil, S.J.; Saven, A.; et al. Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA 2001, 98, 1853–1858.
11. Gillett, C.E.; Miles, D.W.; Ryder, K.; Skilton, D.; Liebman, R.D.; Springall, R.J.; Barnes, D.M.; Hanby, A.M. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J. Pathol. 2001, 193, 433–441.
12. Satriyo,P.B.;Bamodu,O.A.;Chen,J.H.;Aryandono,T.;Haryana,S.M.;Yeh,C.T.;Chao,T.Y.Cadherin11InhibitionDownregulates beta-catenin, Deactivates the Canonical WNT Signalling Pathway and Suppresses the Cancer Stem Cell-Like Phenotype of Triple Negative Breast Cancer. J. Clin. Med. 2019, 8, 148.
13. Waning, D.L.; Guise, T.A.; Mohammad, K.S. A “Connexin” Responsible for the Fatal Attraction of Cancer to Bone. Cell Metab. 2019, 29, 6–8.
14. Marazzi, F.; Orlandi, A.; Manfrida, S.; Masiello, V.; Di Leone, A.; Massaccesi, M.; Moschella, F.; Franceschini, G.; Bria, E.; Gambacorta, M.A.; et al. Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians. Cancers 2020, 12, 2390.
15. Sun, W.; Ge, K.; Jin, Y.; Han, Y.; Zhang, H.; Zhou, G.; Yang, X.; Liu, D.; Liu, H.; Liang, X.J.; et al. Bone-Targeted Nanoplatform Combining Zoledronate and Photothermal Therapy To Treat Breast Cancer Bone Metastasis. ACS Nano 2019, 13, 7556–7567.
16. Danhier, F.; Le Breton, A.; Preat, V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharm. 2012, 9, 2961–2973.
17. Celin, M.R.; Simon, J.C.; Krzak, J.J.; Fial, A.V.; Kruger, K.M.; Smith, P.A.; Harris, G.F. Do Bisphosphonates Alleviate Pain in Children? A Systematic Review. Curr. Osteoporos Rep. 2020, 18, 486–504.
18. Wardley, A.; Davidson, N.; Barrett-Lee, P.; Hong, A.; Mansi, J.; Dodwell, D.; Murphy, R.; Mason, T.; Cameron, D. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: A randomised, crossover study of community vs hospital bisphosphonate administration. Br. J. Cancer 2005, 92, 1869–1876.
19. Niemeyer, C.M. Nanoparticles, proteins ,and nucleicacids: Biotechnology meets materials science. Angew. Chem. Int. Ed. 2001,40, 4128–4158.
20. He, Y.; Huang, Y.; Huang, Z.; Jiang, Y.; Sun, X.; Shen, Y.; Chu, W.; Zhao, C. Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer. J. Control. Release 2017, 264, 76–88.
21. Wang, K.; Guo, C.; Dong, X.; Yu, Y.; Wang, B.; Liu, W.; Chen, D. In Vivo Evaluation of Reduction-Responsive Alendronate Hyaluronan- Curcumin Polymer-Drug Conjugates for Targeted Therapy of Bone Metastatic Breast Cancer. Mol. Pharm. 2018, 15, 2764–2769.
22. Thamake, S.I.; Raut, S.L.; Gryczynski, Z.; Ranjan, A.P.; Vishwanatha, J.K. Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials 2012, 33, 7164–7173.
23. Salerno, M.; Cenni, E.; Fotia, C.; Avnet, S.; Granchi, D.; Castelli, F.; Micieli, D.; Pignatello, R.; Capulli, M.; Rucci, N.; et al. Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr. Cancer Drug Targets 2010, 10, 649–659.
24. Otaka, A.; Yamaguchi, T.; Saisho, R.; Hiraga, T.; Iwasaki, Y. Bone-targeting phospholipid polymers to solubilize the lipophilic anticancer drug. J. Biomed. Mater. Res. A 2020, 108, 2090–2099.
25. Vanderburgh, J.; Hill, J.L.; Gupta, M.K.; Kwakwa, K.A.; Wang, S.K.; Moyer, K.; Bedingfield, S.K.; Merkel, A.R.; d’Arcy, R.; Guelcher, S.A.; et al. Tuning Ligand Density To Optimize Pharmacokinetics of Targeted Nanoparticles for Dual Protection against Tumor-Induced Bone Destruction. ACS Nano 2020, 14, 311–327.
26. Pang, Y.; Fu, Y.; Li, C.; Wu, Z.; Cao, W.; Hu, X.; Sun, X.; He, W.; Cao, X.; Ling, D.; et al. Metal-Organic Framework Nanoparticles for Ameliorating Breast Cancer-Associated Osteolysis. Nano Lett. 2020, 20, 829–840.
27. Cai, S.; Yan, J.; Xiong, H.; Xing, H.; Liu, Y.; Liu, S.; Liu, Z. Aptamer-Functionalized Molybdenum Disulfide Nanosheets for Tumor Cell Targeting and Lysosomal Acidic Environment/NIR Laser Responsive Drug Delivery to Realize Synergetic ChemoPhotothermal Therapeutic Effects. Int. J. Pharm. 2020, 590, 119948.